Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower) 2 years [clinicaltrials_resource:bdbd0bf672330f7cda86d2831539a994]
The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower) 2 years [clinicaltrials_resource:bdbd0bf672330f7cda86d2831539a994]
The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
Bio2RDF identifier
bdbd0bf672330f7cda86d2831539a994
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bdbd0bf672330f7cda86d2831539a994
measure [clinicaltrials_vocabulary:measure]
Proportion of progression to t ...... se (MMSE score of 15 or lower)
time frame [clinicaltrials_vocabulary:time-frame]
description
The control group involves a s ...... am for caregivers of patients.
identifier
clinicaltrials_resource:bdbd0bf672330f7cda86d2831539a994
title
Proportion of progression to t ...... score of 15 or lower) 2 years
@en
type
label
Proportion of progression to t ...... d0bf672330f7cda86d2831539a994]
@en